Bringing you live news and features since 2006 

MSCI partners with Royalty Pharma to launch life sciences indexes

RELATED TOPICS​

MSCI Inc is partnering with Royalty Pharma to expand MSCI’s thematic index suite with the launch of new indexes that aim to capture long-term, cutting edge themes that will disrupt the life sciences, biotechnology and pharmaceutical industry groups. 

The initial indexes will measure the performance of companies focused on delivering new and innovative therapeutic treatments related to virology and oncology. Royalty Pharma will provide expertise on various medical conditions, clinical trials, transformative therapies and technologies that may lead to breakthrough medical treatments that will assist MSCI to design a classification framework and index methodologies. 

Henry Fernandez, Chairman and Chief Executive Officer of MSCI, says: “The Covid-19 pandemic has had a profound impact on all aspects of society and has proven to be an accelerant for long-term, structural changes, particularly in the life sciences. As we have seen during this time, life sciences companies are pivotal to shaping and advancing the healthcare industry and have been critical to the development of approaches for prevention and treatment of diseases. MSCI is thrilled to partner with Royalty Pharma to design thematic indexes that capture companies at the forefront of this evolving landscape and having a positive impact on the future of our world.” 

Pablo Legorreta, Founder and Chief Executive Officer of Royalty Pharma, says: “As a leading funder of innovation in life sciences, we are extremely excited to collaborate with MSCI to develop innovative index solutions that will be licensed as the basis for indexed financial products such as ETFs targeting this dynamic sector. This collaboration leverages Royalty Pharma’s deep clinical and scientific knowledge built over decades, as well as the unique capabilities of our Strategy and Analytics team. This venture represents another example of Royalty Pharma’s creative approach to monetising its existing intellectual capital through the creation of indexes that support investment in life sciences.” 

The indexes are planned to launch later this year. 
 

Latest News

Amundi’s ETF Market Flows Analysis for May finds that global ETF inflows were EUR105.1 billion with US-domiciled equity funds accounting..
MerQube has announced the appointment of Dave Mueller as Chief Financial Officer. Mueller brings 17 years experience operating in corporate..
Northern Trust Asset Management (NTAM), has announced that David Abner is joining as Head of Global ETFs and Funds...
Nvidia’s market cap surge to more than USD3 trillion making it the second most valuable company in the world almost..

Related Articles

CN Tower, Toronto
The winners were announced in the second ETF Express Canadian awards at the event held at The Quay in Toronto,...
Darren Johnson, Komainu
Custody specialist, Komainu, was launched in 2018 as a joint venture between Nomura, digital-asset investment manager, CoinShares and blockchain business,...
Stuart Chaussee
In January this year, global data and business intelligence platform, Statista reported that there are now more than 8000 ETFs...
Ethereum coin
Last week saw Australia launch spot bitcoin ETFs, with Matteo Greco, Research Analyst at Fineqia International, writing that Monochrome Asset...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by